Is GHRS or BIOA more profitable?

GH Research has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. GH Research's return on equity of -20.07% beat BioAge Labs' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% BioAge Labs -912.26% -28.99% -27.09%

Does the media prefer GHRS or BIOA?

In the previous week, GH Research and GH Research both had 1 articles in the media. GH Research's average media sentiment score of 0.00 equaled BioAge Labs'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BIOA or OCUL?

In the previous week, Ocular Therapeutix had 7 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Ocular Therapeutix and 1 mentions for BioAge Labs. Ocular Therapeutix's average media sentiment score of 0.69 beat BioAge Labs' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIOA or CMPS?

In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. Compass Pathways' average media sentiment score of 0.66 beat BioAge Labs' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIOA or ANIP?

In the previous week, ANI Pharmaceuticals had 18 more articles in the media than BioAge Labs. MarketBeat recorded 19 mentions for ANI Pharmaceuticals and 1 mentions for BioAge Labs. ANI Pharmaceuticals' average media sentiment score of 0.74 beat BioAge Labs' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Is PRGO or BIOA more profitable?

Perrigo has a net margin of -41.85% compared to BioAge Labs' net margin of -912.26%. Perrigo's return on equity of 11.25% beat BioAge Labs' return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% BioAge Labs -912.26% -28.99% -27.09%

Does the media refer more to PRGO or BIOA?

In the previous week, Perrigo had 4 more articles in the media than BioAge Labs. MarketBeat recorded 5 mentions for Perrigo and 1 mentions for BioAge Labs. Perrigo's average media sentiment score of 0.40 beat BioAge Labs' score of 0.00 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioAge Labs (BIOA) Competitors

$9.48 -0.21 (-2.17%)

As of 08/21/2026 04:00 PM Eastern

Compare

BIOA vs. GHRS, OCUL, CMPS, ANIP, and PRGO

Should you buy BioAge Labs stock or one of its competitors? BioAge Labs's main competitors and comparable companies include GH Research (GHRS), Ocular Therapeutix (OCUL), Compass Pathways (CMPS), ANI Pharmaceuticals (ANIP), and Perrigo (PRGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BioAge Labs compare to GH Research?

GH Research (NASDAQ:GHRS) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

GH Research has higher earnings, but lower revenue than BioAge Labs. GH Research is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
BioAge Labs	$10.36M	42.02	-$80.61M	-$2.38	N/A

GH Research has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. GH Research's return on equity of -20.07% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
BioAge Labs	-912.26%	-28.99%	-27.09%

GH Research currently has a consensus target price of $45.00, suggesting a potential upside of 58.84%. BioAge Labs has a consensus target price of $36.57, suggesting a potential upside of 285.77%. Given BioAge Labs' higher possible upside, analysts clearly believe BioAge Labs is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

GH Research has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

In the previous week, GH Research and GH Research both had 1 articles in the media. GH Research's average media sentiment score of 0.00 equaled BioAge Labs'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 17.5% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GH Research beats BioAge Labs on 10 of the 13 factors compared between the two stocks.

How does BioAge Labs compare to Ocular Therapeutix?

BioAge Labs (NASDAQ:BIOA) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

59.2% of Ocular Therapeutix shares are owned by institutional investors. 17.5% of BioAge Labs shares are owned by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioAge Labs has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.36M	42.02	-$80.61M	-$2.38	N/A
Ocular Therapeutix	$51.95M	46.84	-$265.94M	-$1.42	N/A

In the previous week, Ocular Therapeutix had 7 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Ocular Therapeutix and 1 mentions for BioAge Labs. Ocular Therapeutix's average media sentiment score of 0.69 beat BioAge Labs' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

BioAge Labs presently has a consensus price target of $36.57, suggesting a potential upside of 285.77%. Ocular Therapeutix has a consensus price target of $25.75, suggesting a potential upside of 132.40%. Given BioAge Labs' higher probable upside, equities analysts plainly believe BioAge Labs is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Ocular Therapeutix has a net margin of -579.10% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

Summary

Ocular Therapeutix beats BioAge Labs on 9 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Compass Pathways?

BioAge Labs (NASDAQ:BIOA) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

BioAge Labs has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

Compass Pathways has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Compass Pathways	N/A	-49.63%	-13.08%

46.2% of Compass Pathways shares are owned by institutional investors. 17.5% of BioAge Labs shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. Compass Pathways' average media sentiment score of 0.66 beat BioAge Labs' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs presently has a consensus target price of $36.57, suggesting a potential upside of 285.77%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 75.22%. Given BioAge Labs' higher possible upside, equities analysts plainly believe BioAge Labs is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

BioAge Labs has higher revenue and earnings than Compass Pathways. BioAge Labs is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.36M	42.02	-$80.61M	-$2.38	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Compass Pathways beats BioAge Labs on 9 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to ANI Pharmaceuticals?

BioAge Labs (NASDAQ:BIOA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 17.5% of BioAge Labs shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ANI Pharmaceuticals had 18 more articles in the media than BioAge Labs. MarketBeat recorded 19 mentions for ANI Pharmaceuticals and 1 mentions for BioAge Labs. ANI Pharmaceuticals' average media sentiment score of 0.74 beat BioAge Labs' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

BioAge Labs presently has a consensus price target of $36.57, indicating a potential upside of 285.77%. ANI Pharmaceuticals has a consensus price target of $105.83, indicating a potential upside of 40.46%. Given BioAge Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe BioAge Labs is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ANI Pharmaceuticals has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.36M	42.02	-$80.61M	-$2.38	N/A
ANI Pharmaceuticals	$883.37M	1.96	$78.34M	$4.64	16.24

ANI Pharmaceuticals has a net margin of 11.07% compared to BioAge Labs' net margin of -912.26%. ANI Pharmaceuticals' return on equity of 27.37% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

ANI Pharmaceuticals beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Perrigo?

Perrigo (NYSE:PRGO) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

95.9% of Perrigo shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 17.5% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Perrigo has a net margin of -41.85% compared to BioAge Labs' net margin of -912.26%. Perrigo's return on equity of 11.25% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, Perrigo had 4 more articles in the media than BioAge Labs. MarketBeat recorded 5 mentions for Perrigo and 1 mentions for BioAge Labs. Perrigo's average media sentiment score of 0.40 beat BioAge Labs' score of 0.00 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Perrigo currently has a consensus price target of $19.33, indicating a potential upside of 35.96%. BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 285.77%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BioAge Labs has lower revenue, but higher earnings than Perrigo. BioAge Labs is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
BioAge Labs	$10.36M	42.02	-$80.61M	-$2.38	N/A

Summary

Perrigo and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$435.10M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-3.98	789.80	272.88	24.24
Price / Sales	42.02	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	1.16	11.89	13.05	6.20
Net Income	-$80.61M	$2.81B	$3.47B	$348.59M
7 Day Performance	-10.57%	1.77%	2.09%	0.08%
1 Month Performance	-56.71%	3.85%	6.64%	3.88%
1 Year Performance	105.64%	6.56%	25.02%	16.98%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	2.2717 of 5 stars	$9.48 -2.2%	$36.57 +285.8%	+105.6%	$435.10M	$10.36M	N/A	N/A
GHRS GH Research	2.1384 of 5 stars	$29.59 -2.2%	$45.00 +52.1%	+116.6%	$2.03B	N/A	N/A	10	Positive News
OCUL Ocular Therapeutix	3.3383 of 5 stars	$9.21 +0.2%	$25.75 +179.7%	-9.9%	$2.02B	$51.95M	N/A	230	Positive News Gap Up
CMPS Compass Pathways	2.4623 of 5 stars	$13.17 -2.8%	$23.36 +77.4%	+189.2%	$1.77B	N/A	N/A	120
ANIP ANI Pharmaceuticals	4.2086 of 5 stars	$76.42 -2.3%	$105.83 +38.5%	-17.2%	$1.74B	$923.71M	16.48	600	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. GHRS, OCUL, CMPS, ANIP, and PRGO

How does BioAge Labs compare to GH Research?

Summary

How does BioAge Labs compare to Ocular Therapeutix?

Summary

How does BioAge Labs compare to Compass Pathways?

Summary

How does BioAge Labs compare to ANI Pharmaceuticals?

Summary

How does BioAge Labs compare to Perrigo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. GHRS, OCUL, CMPS, ANIP, and PRGO

How does BioAge Labs compare to GH Research?

Which has higher valuation & earnings, GHRS or BIOA?

Is GHRS or BIOA more profitable?

Do analysts recommend GHRS or BIOA?

Which has more volatility & risk, GHRS or BIOA?

Does the media prefer GHRS or BIOA?

Do insiders and institutionals hold more shares of GHRS or BIOA?

Summary

How does BioAge Labs compare to Ocular Therapeutix?

Do institutionals and insiders have more ownership in BIOA or OCUL?

Which has stronger valuation and earnings, BIOA or OCUL?

Does the media favor BIOA or OCUL?

Which has more volatility & risk, BIOA or OCUL?

Do analysts rate BIOA or OCUL?

Is BIOA or OCUL more profitable?

Summary

How does BioAge Labs compare to Compass Pathways?

Which has more volatility and risk, BIOA or CMPS?

Is BIOA or CMPS more profitable?

Do insiders and institutionals have more ownership in BIOA or CMPS?

Does the media favor BIOA or CMPS?

Do analysts prefer BIOA or CMPS?

Which has higher earnings & valuation, BIOA or CMPS?

Summary

How does BioAge Labs compare to ANI Pharmaceuticals?

Do institutionals & insiders have more ownership in BIOA or ANIP?

Does the media favor BIOA or ANIP?

Which has more volatility and risk, BIOA or ANIP?

Do analysts rate BIOA or ANIP?

Which has stronger valuation and earnings, BIOA or ANIP?

Is BIOA or ANIP more profitable?

Summary

How does BioAge Labs compare to Perrigo?

Which has more risk & volatility, PRGO or BIOA?

Do insiders and institutionals have more ownership in PRGO or BIOA?

Is PRGO or BIOA more profitable?

Does the media refer more to PRGO or BIOA?

Do analysts recommend PRGO or BIOA?

Which has preferable valuation and earnings, PRGO or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools